4//SEC Filing
Coughlin Timothy 4
Accession 0001376043-25-000004
CIK 0001438533other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 4:05 PM ET
Size
12.9 KB
Accession
0001376043-25-000004
Insider Transaction Report
Form 4
Coughlin Timothy P
Director
Transactions
- Exercise/Conversion
Director stock option (right to buy)
2025-10-31−8,000→ 0 totalExercise: $16.33Exp: 2026-05-17→ Common Stock (8,000 underlying) - Exercise/Conversion
Director stock option (right to buy)
2025-10-31−10,000→ 0 totalExercise: $17.44Exp: 2027-05-16→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2025-10-31$17.44/sh+10,000$174,400→ 73,500 total - Exercise/Conversion
Common Stock
2025-10-31$16.33/sh+8,000$130,640→ 63,500 total - Sale
Common Stock
2025-10-31$35.03/sh−18,000$630,601→ 55,500 total
Footnotes (3)
- [F1]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F2]The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The stock option is fully vested and exercisable.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001376043
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 4:05 PM ET
- Size
- 12.9 KB